Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2009. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically detailing an increase in their interests in the company's ordinary shares and American Depositary Receipts (ADRs).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to specific share purchase transactions:
- Ordinary shares purchase price: £12.77 per share.
- ADRs purchase price: $39.62 per ADR.
- Transaction date: October 15, 2009.
Material Changes
The filing reports an increase in shareholdings for various directors and executives. These transactions were executed following the re-investment of dividends paid to shareholders on October 8, 2009. No material changes to the company's business operations or financial position are disclosed in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or discussion of unusual items. It is strictly a regulatory disclosure of insider trading activity in compliance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Verify the dividend reinvestment plan details for the October 8, 2009 payment date.
- Confirm the total number of shares and ADRs acquired by each listed director (e.g., Mr. J R Stéphenne acquired 435.92 ADRs).
- Note that this filing does not contain quarterly or annual financial results; investors should refer to Form 20-F for comprehensive financial data.